Christopher D. Herzog, Ph.D.

"Christopher Herzog"
Mean distance: 15.37 (cluster 19)


Sign in to add mentor
Tim Otto grad student 2000 Rutgers, New Brunswick
 (Regeneration of olfactory receptor neurons: Anatomical and behavioral effects of growth factor administration.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Warren Olanow C, Bartus RT, Baumann TL, et al. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology. 78: 248-57
Bartus RT, Kordower JH, Johnson EM, et al. (2015) Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiology of Disease. 78: 162-71
Rafii MS, Baumann TL, Bakay RA, et al. (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 571-81
Herzog CD, Brown L, Kruegel BR, et al. (2013) Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiology of Disease. 58: 38-48
Bartus RT, Baumann TL, Siffert J, et al. (2013) Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 80: 1698-701
Bartus RT, Baumann TL, Brown L, et al. (2013) Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiology of Aging. 34: 35-61
Herzog CD, Bishop KM, Brown L, et al. (2011) Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Delivery and Translational Research. 1: 361-82
Bartus RT, Brown L, Wilson A, et al. (2011) Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiology of Disease. 44: 38-52
Bartus RT, Herzog CD, Chu Y, et al. (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 27-36
Herzog CD, Brown L, Gammon D, et al. (2009) Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 64: 602-12; discussion 6
See more...